{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:44:15Z","timestamp":1767134655260,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd001908.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2014,2,5]],"date-time":"2014-02-05T00:00:00Z","timestamp":1391558400000}}],"reference-count":30,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001908.pub3","type":"journal-article","created":{"date-parts":[[2014,2,5]],"date-time":"2014-02-05T11:28:43Z","timestamp":1391599723000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tiagabine add-on for drug-resistant partial epilepsy"],"prefix":"10.1002","author":[{"given":"Jennifer","family":"Pulman","sequence":"first","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Clinical Sciences Centre for Research and Education, Lower Lane Fazakerley Liverpool Merseyside UK L9 7LJ"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane L","family":"Hutton","sequence":"additional","affiliation":[{"name":"University of Warwick; Department of Statistics; Coventry UK CV4 7AL"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, University of Liverpool; Department of Molecular and Clinical Pharmacology; Clinical Sciences Centre for Research and Education, Lower Lane Fazakerley Liverpool Merseyside UK L9 7LJ"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,2,5]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD001908.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1046\/j.1528-1157.2001.36500.x","article-title":"Tiagabine: efficacy and safety in adjunctive treatment of partial seizures","volume":"42","author":"Crawford","year":"2001","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001908.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.yebeh.2005.01.002","article-title":"Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy","volume":"6","author":"Fritz","year":"2005","journal-title":"Epilepsy & Behavior"},{"issue":"3","key":"10.1002\/14651858.CD001908.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0920-1211(96)00084-8","article-title":"Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy","volume":"25","author":"Kalviainen","year":"1996","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD001908.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0920-1211(97)00082-X","article-title":"A double-blind, placebo-controlled trial of tiagabine given three-times daily as add-on therapy for refractory partial seizures","volume":"30","author":"Kalviainen","year":"1998","journal-title":"Epilepsy Research"},{"issue":"1","key":"10.1002\/14651858.CD001908.pub3-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/0920-1211(95)00006-V","article-title":"Adjunctive treatment of partial seizures with tiagabine: a placebo-controlled trial","volume":"21","author":"Richens","year":"1995","journal-title":"Epilepsy Research"},{"issue":"1","key":"10.1002\/14651858.CD001908.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1059-1311(05)80160-8","article-title":"Neuropsychological effects of tiagabine, a potential new antiepileptic drug","volume":"3","author":"Sveinbjornsdottir","year":"1994","journal-title":"Seizure"},{"key":"10.1002\/14651858.CD001908.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/archneur.1997.00550170069016","article-title":"Tiagabine therapy for complex partial seizures: a dose-frequency study","volume":"54","author":"Sachdeo","year":"1997","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001908.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1212\/WNL.48.4.1025","article-title":"Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy","volume":"48","author":"Dodrill","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD001908.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/archneur.55.1.56","article-title":"Tiagabine for complex partial seizures: a randomized, add-on, dose-response trial","volume":"55","author":"Uthman","year":"1998","journal-title":"Archives of Neurology"},{"issue":"2","key":"10.1002\/14651858.CD001908.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.seizure.2004.09.002","article-title":"A randomised open-label study of tiagabine given two or three times daily in refractory epilepsy","volume":"14","author":"Arroyo","year":"2005","journal-title":"Seizure"},{"issue":"1","key":"10.1002\/14651858.CD001908.pub3-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0896-6974(94)00015-R","article-title":"Efficacy and tolerability of tiagabine: results of an add-on study in patients with refractory partial seizures","volume":"8","author":"Bauer","year":"1995","journal-title":"Journal of Epilepsy"},{"issue":"4","key":"10.1002\/14651858.CD001908.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1212\/WNL.48.4.1032","article-title":"A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures","volume":"48","author":"Gustavson","year":"1997","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD001908.pub3-BIB0013|cit13","first-page":"S147","article-title":"Single-blind study of safety, tolerability and preliminary efficacy of tiagabine as adjunctive treatment of children with epilepsy","volume":"36 Suppl","author":"Uldall","year":"1995","journal-title":"Epilepsia"},{"issue":"11","key":"10.1002\/14651858.CD001908.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1111\/j.1528-1157.2000.tb00110.x","article-title":"Quality of life and behavioural outcome measures in randomized controlled trials of antiepileptic drugs: a systematic review of reporting standards","volume":"41","author":"Baker","year":"2000","journal-title":"Epilepsia"},{"issue":"10","key":"10.1002\/14651858.CD001908.pub3-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1528-1157.1998.tb01295.x","article-title":"Neuropsychological outcomes in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards","volume":"39","author":"Cochrane","year":"1998","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001908.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S0140-6736(95)91208-8","article-title":"Remission of epilepsy: results from the national general practice study of epilepsy","volume":"346","author":"Cockerell","year":"1995","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD001908.pub3-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Proposal for revised classification of epilepsies and epileptic syndromes","volume":"30","author":"Commission on Classification and Terminology of the International League Against Epilepsy","year":"1989","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD001908.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1212\/WNL.48.4.1025","article-title":"Cognitive and quality of life effects of differing dosages of tiagabine in epilepsy","volume":"48","author":"Dodrill","year":"1997","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD001908.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1528-1157.1993.tb02586.x","article-title":"Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984","volume":"34","author":"Hauser","year":"1993","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001908.pub3-BIB0020|cit20","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2010"},{"issue":"3","key":"10.1002\/14651858.CD001908.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0920-1211(96)00084-8","article-title":"Long-term cognitive and EEG effects of tiagabine in drug-resistant partial epilepsy","volume":"25","author":"Kalviainen","year":"1996","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD001908.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1136\/bmj.c365","article-title":"The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews","volume":"340","author":"Kirkham","year":"2010","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD001908.pub3-BIB0023|cit23","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]. The Cochrane Collaboration, 2009 www.cochrane-handbook.org"},{"issue":"7066","key":"10.1002\/14651858.CD001908.pub3-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1136\/bmj.313.7066.1169","article-title":"New antiepileptic drugs: a systematic review of their efficacy and tolerability","volume":"313","author":"Marson","year":"1996","journal-title":"BMJ"},{"issue":"8","key":"10.1002\/14651858.CD001908.pub3-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1111\/j.1528-1157.1997.tb01251.x","article-title":"The new antiepileptic drugs: a systematic review of their efficacy and tolerability","volume":"38","author":"Marson","year":"1997","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001908.pub3-BIB0026|cit26","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4899-3242-6","volume-title":"Generalized Linear Models","author":"McCullagh","year":"1989"},{"key":"10.1002\/14651858.CD001908.pub3-BIB0027|cit27","article-title":"Tiagabine","volume-title":"Mechanisms of Action in Antiepileptic Drugs","author":"Ostergaard","year":"1995"},{"issue":"5","key":"10.1002\/14651858.CD001908.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1136\/jnnp.61.5.433","article-title":"Epidemiology of the epilepsies","volume":"61","author":"Sander","year":"1996","journal-title":"Journal of Neurology, Neurosurgery, & Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD001908.pub3-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1059-1311(05)80160-8","article-title":"Neuropsychological effects of tiagabine, a potential new antiepileptic drug","volume":"3","author":"Sveinbjornsdottir","year":"1994","journal-title":"Seizure"},{"issue":"5","key":"10.1002\/14651858.CD001908.pub3-BIB0030|cit30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001908.pub2","article-title":"Tiagabine add-on for drug-resistant partial epilepsy","author":"Pulman","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd001908.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,10,14]],"date-time":"2019-10-14T00:00:00Z","timestamp":1571011200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD001908.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T17:06:54Z","timestamp":1628528814000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD001908.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2014,2,5]]},"references-count":30,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001908.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,5]]}}}